Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-hodgkin's lymphoma Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Lymphoma, B-Cell
  • Neoplasm Recurrence, Local
  • Radioimmunotherapy
  • Radiotherapy Dosage

abstract

  • Dose-escalated (90)Y ibritumomab tiuxetan may be safely combined with high-dose BEAM with autologous transplantation and has the potential to be more effective than standard-dose radioimmunotherapy. Careful dosimetry is required to avoid toxicity and undertreatment.

publication date

  • April 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC2668971

Digital Object Identifier (DOI)

  • 10.1200/JCO.2008.19.2245

PubMed ID

  • 19255322

Additional Document Info

start page

  • 1653

end page

  • 9

volume

  • 27

number

  • 10